Clinical Trials on Non-alcoholic Steatohepatitis (NASH) in United Kingdom

Total 532 results

Regeneron Pharmaceuticals

Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

Non-alcoholic Steatohepatitis (NASH) | Metabolic Dysfunction Associated Steatohepatitis (MASH)

United States, Korea, Republic of, Puerto Rico, Japan
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Corcept Therapeutics

Recruiting

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH)

United States
Aligos Therapeutics

Recruiting

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (HERALD)

Nonalcoholic Steatohepatitis | NASH | MASH | Metabolic Dysfunction-Associated Steatohepatitis

United States
Eccogene

Recruiting

FTIH of ECC4703 in Healthy Volunteers

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
Hepanova Inc.

Unknown

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

Non-Alcoholic Steatohepatitis (NASH)

United States
Pfizer

Completed

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Non-Alcoholic Steatohepatitis(NASH)

United States
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Poxel SA

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

NASH - Nonalcoholic Steatohepatitis

United Kingdom
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Non-alcoholic Steatohepatitis (NASH)

Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
Genfit
Premier Research Group plc; Naturalpha

Completed

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

United States, Belgium, France, Germany, Italy, Netherlands, Romania, Spain, United Kingdom
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
NorthSea Therapeutics B.V.

Active, not recruiting

A Phase 2b Study of Icosabutate in Fatty Liver Disease (ICONA)

Non Alcoholic Steatohepatitis (NASH)

United States, Puerto Rico
Regeneron Pharmaceuticals

Terminated

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis (NASH)

Brazil, United States, Puerto Rico, Korea, Republic of, Mexico
University of Minnesota

Recruiting

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Galectin Therapeutics Inc.

Completed

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Non-Alcoholic Steatohepatitis (NASH)

United States
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
University of Illinois at Chicago

Terminated

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH) | Hepatic Steatosis

United States
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Milton S. Hershey Medical Center

Recruiting

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

Exercise | NASH - Nonalcoholic Steatohepatitis | NASH | Liver

United States
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH)

United States
Alnylam Pharmaceuticals

Terminated

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis | NASH

United States, Bulgaria, United Kingdom, Belgium, Turkey
Cirius Therapeutics, Inc.
Chiltern International Inc.

Completed

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (EMMINENCE)

Non-alcoholic Fatty Liver Disease | NASH - Nonalcoholic Steatohepatitis | Non-alcoholic Steatohepatitis

United States
University of Alabama at Birmingham
AstraZeneca

Terminated

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

United States
Novartis Pharmaceuticals
Allergan

Completed

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis (TANDEM)

Non-alcoholic Steatohepatitis (NASH)

United States, Belgium, Spain, Canada, Argentina, Israel, Germany, France, Italy, Turkey, Singapore, Russian Federation, United Kingdom, Czechia, Egypt, India, Latvia
Vanderbilt University Medical Center

Terminated

Palliative Care for Non-Malignant Diseases (COMPASS Trial) (COMPASS)

Liver Diseases | Liver Cirrhosis | NASH (Non-Alcoholic Steatohepatitis)

United States
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States
Enanta Pharmaceuticals, Inc
Covance

Completed

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NASH - Nonalcoholic Steatohepatitis

United States
Enanta Pharmaceuticals, Inc

Completed

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

United States
Metacrine, Inc.

Completed

Study to Evaluate MET642 in Patients With NASH

NASH - Nonalcoholic Steatohepatitis

United States
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis | MASH With Fibrosis

United States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain
Perspectum

Recruiting

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NASH - Nonalcoholic Steatohepatitis

United States
Massachusetts General Hospital

Recruiting

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NASH - Nonalcoholic Steatohepatitis

United States
Meridian Bioscience, Inc.
Bristol-Myers Squibb

Completed

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NASH - Nonalcoholic Steatohepatitis

United States
Gilead Sciences

Completed

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Nonalcoholic Steatohepatitis (NASH)

United States
Navidea Biopharmaceuticals

Completed

An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Nonalcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis

United States
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Rivus Pharmaceuticals, Inc.

Completed

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

NASH - Nonalcoholic Steatohepatitis

United States
Rivus Pharmaceuticals, Inc.

Completed

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

NASH - Nonalcoholic Steatohepatitis

United States
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NASH - Nonalcoholic Steatohepatitis

United States
Lipocine Inc.

Active, not recruiting

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NASH - Nonalcoholic Steatohepatitis

United States
University of California, San Francisco

Completed

Spironolactone Therapy In Young Women With NASH

NASH - Nonalcoholic Steatohepatitis

United States
Hepagene (Shanghai) Co., Ltd.

Active, not recruiting

Phase 2a Study of HPG1860 in Subjects With NASH (RISE)

NASH - Nonalcoholic Steatohepatitis

United States
Rivus Pharmaceuticals, Inc.

Completed

Ascending Dose Study of HU6 in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

United States
CymaBay Therapeutics, Inc.

Terminated

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States

Clinical Trials on Non-alcoholic Steatohepatitis (NASH) in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations